Brief: Shenzhen Neptunus Interlong Bio-Technique Says Unit Entered Distribution Agreement
22/07/2022 16:34
July 22 (Reuters) - Shenzhen Neptunus Interlong
Bio-technique 8329.HK :
* UNIT ENTERED INTO DISTRIBUTION AGREEMENT WITH NEPTUNUS
RESEARCH
* NEPTUNUS CHANGJIAN WILL PURCHASE VARIOUS PHARMA PRODUCTS
FROM
NEPTUNUS RESEARCH FOR DISTRIBUTION IN PRC
* PROPOSED PURCHASE CAPS FOR 2022, 2023 AND 2024 ARE RMB10
MILLION, RMB11 MILLION AND RMB12.1 MILLION, RESPECTIVELY
Further company coverage: 8329.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Neptunus Interlong Bio-technique
See all newsBrief: Shenzhen Neptunus Interlong Bio-Technique's Unit Enters Into JV Agreement With Huikang Bio-Technology
China's Neptunus Interlong H1 revenue falls
Brief: Shenzhen Neptunus Interlong Bio-Technique Expects Net Profit Attributable To Owners Of RMB 7 Million For 2026 Interim Period
Brief: Shenzhen Neptunus Interlong Bio-Technique Posts FY Loss & Total Comprehensive Expenses Attributable RMB40.7 Million
Brief: Shenzhen Neptunus Interlong Bio-Technique Sees FY Net Loss Attributable Of RMB40 Million